
Incyte Corporation
NASDAQ:INCY
58.96 (USD) • At close May 9, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Incyte Corporation |
Symbool | INCY |
Munteenheid | USD |
Prijs | 58.96 |
Beurswaarde | 11,412,887,200 |
Dividendpercentage | 0% |
52-weken bereik | 52.81 - 83.95 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Herve Hoppenot |
Website | https://www.incyte.com |
An error occurred while fetching data.
Over Incyte Corporation
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)